On 5th March, 2019, FDA approves Spravato(esketamine) nasal spray, a fast-acting novel antidepressant to be used in conjunction with oral antidepressants for treatment refractory depression in adults.
For related information see the American Journal of of psychiatry https://ajp.psychiatryonline.org/…/1…/appi.ajp.2018.17060720